Allarity Therapeutics, Inc. (ALLR): Entry into a Material Definitive Agreement

Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts Investigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observations Adds platinum-refractory patients as well as those with ha

Event · Clinical / regulatory
Product
stenoparib
Milestone
trial start
Indication
advanced ovarian cancer

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 17, 2026, 12:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ALLR
Bullish
medium confidence
Mentioned
$ALLR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ALLRBullishMed
01

Why it matters

By expanding eligibility to primary platinum-refractory and non-RECIST measurable disease, the company increases trial accessibility and the breadth of evidence it can generate across distinct high-unmet-need populations.

02

Market read

Protocol expansion is a tangible catalyst for clinical-stage biotech positioning, but it is not yet a new efficacy datapoint.

03

What to watch

Key readouts and statistical power depend on enrollment pace and event timing; the cited OS comparison (~22 months vs ~16 months) is contextual and may not be directly comparable across studies.

Relevance 6/10Novelty 6/10Timing: today’s SEC 8-K filing confirms Phase 2 protocol expansion

Background

The 8-K (Item 1.01) furnishes an exhibit describing Allarity’s Phase 2 stenoparib (2X-121) trial in advanced ovarian cancer and an amended protocol adding two additional patient groups evaluated separately.

Company-level read

Ticker impact

$ALLRBullishMedium confidence
Context

Allarity confirmed expanded eligibility for its Phase 2 stenoparib advanced ovarian cancer trial, adding primary platinum-refractory and non-RECIST measurable cohorts.

Expected impact

Likely upward bias as investors price in improved enrollment, broader efficacy signals, and potential acceleration toward FDA development.

Evidence & confidence

The filing is a primary disclosure of protocol eligibility changes plus supportive prior observations (durable benefit, OS, and responses), which can improve trial informativeness even without new efficacy data yet.

Market effects

Supports sentiment for PARP/WNT pathway oncology development and for trial designs that include platinum-refractory and non-RECIST measurable disease.

Limited, company-specific US-listed biotech news with no clear regional macro linkage.

Moderate for global oncology investors tracking stenoparib’s Phase 2 program and cohort expansion strategy.

Counterpoint

Eligibility expansion does not guarantee efficacy; added cohorts may dilute effect sizes or increase heterogeneity, and no new efficacy endpoints are reported in this filing.

Key entities

  • Allarity Therapeutics, Inc.

    NASDAQ-listed clinical-stage pharmaceutical company developing stenoparib (2X-121).

  • Stenoparib (2X-121)

    Orally available dual PARP and tankyrase inhibitor being studied in ovarian cancer Phase 2.

  • Phase 2 ovarian cancer trial

    Ongoing Phase 2 study whose eligibility was expanded to additional platinum-refractory and non-RECIST measurable cohorts.

Related articles

$ALLRMedAI 8/10

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development

Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development - Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SP

$ALLRMed

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company

$ALLRMed

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when